tradingkey.logo

Sol Gel Technologies Ltd

SLGL
33.500USD
-2.000-5.63%
Cierre 11/04, 16:00ETCotizaciones retrasadas 15 min
93.32MCap. mercado
PérdidaP/E TTM

Sol Gel Technologies Ltd

33.500
-2.000-5.63%

Más Datos de Sol Gel Technologies Ltd Compañía

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Información de Sol Gel Technologies Ltd

Símbolo de cotizaciónSLGL
Nombre de la empresaSol Gel Technologies Ltd
Fecha de salida a bolsaFeb 01, 2018
Director ejecutivo- -
Número de empleados34
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
DirecciónGolda Meir 7
CiudadNESS-ZIONA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal- -
Teléfono97289313433
Sitio Webhttp://www.sol-gel.com
Símbolo de cotizaciónSLGL
Fecha de salida a bolsaFeb 01, 2018
Director ejecutivo- -

Ejecutivos de Sol Gel Technologies Ltd

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: mar., 4 de nov
Actualizado: mar., 4 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
M.Arkin Dermatology, Ltd.
64.86%
Arkin (Moshe)
5.14%
Opaleye Management Inc.
5.00%
Migdal Insurance and Financial Holdings Ltd
4.41%
Raymond James Financial Services Advisors, Inc.
0.28%
Otro
20.31%
Accionistas
Accionistas
Proporción
M.Arkin Dermatology, Ltd.
64.86%
Arkin (Moshe)
5.14%
Opaleye Management Inc.
5.00%
Migdal Insurance and Financial Holdings Ltd
4.41%
Raymond James Financial Services Advisors, Inc.
0.28%
Otro
20.31%
Tipos de accionistas
Accionistas
Proporción
Corporation
64.86%
Investment Advisor
9.43%
Individual Investor
5.14%
Hedge Fund
5.00%
Insurance Company
4.41%
Research Firm
0.29%
Otro
10.86%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
35
533.06K
19.14%
-233.10K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Opaleye Management Inc.
139.39K
5%
+139.39K
--
Aug 22, 2025
Migdal Insurance and Financial Holdings Ltd
122.75K
4.41%
--
--
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
7.81K
0.28%
-871.00
-10.03%
Jun 30, 2025
UBS Financial Services, Inc.
7.34K
0.26%
+3.53K
+92.62%
Jun 30, 2025
Morgan Stanley & Co. LLC
5.33K
0.19%
-3.90K
-42.24%
Jun 30, 2025
Raymond James & Associates, Inc.
2.68K
0.1%
+162.00
+6.44%
Jun 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
-200.00
-38.76%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
308.00
0.01%
-1.00
-0.32%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI